Navigation Links
Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
Date:12/16/2010

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.  

"We are very encouraged by the progress made to date in our Factor VIIa program, the most advanced program within Catalyst's hemostasis franchise," said Nassim Usman, Ph.D., Catalyst's CEO.  "In addition to our work with Pfizer, Catalyst has independently achieved significant progress in engineering highly differentiated recombinant human Factor IX and Xa variants for acute and prophylactic treatment of bleeding disorders, including both hemophilia and non-hemophilia indications.  Catalyst expects to expand and strengthen this pipeline of novel engineered proteases in the coming year." 

In June 2009 Catalyst and Wyeth LLC (the successor to Wyeth), a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding, and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments.  

About Catalyst Biosciences  Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases.  Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase™ therapeutics.  Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation.  Catalyst has ongoing research, development, and license agreements with Wyeth Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc. and MedImmune, LLC, the global biologics unit of AstraZeneca plc.  Catalyst is privately held with backing by leading venture firms, including Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures, and Sofinnova Ventures.  For more information, please visit www.catbio.com.Catalyst Biosciences, Inc.

William J. Dawson

Chief Financial Officer

+1.650.871.0761

info@catbio.com

BCC Partners for Catalyst Biosciences

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
2. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
3. Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
4. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
5. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
6. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
7. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
8. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
9. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... heute bekannt, dass sie einen entscheidenden Meilenstein ... haben: Ein Aufruf zum Handeln, um Patientenresultate ... Veröffentlichung trägt zu Fortschritten im Verständnis der ... hervor, ein Bewusstsein für Hepatische Enzephalopathie in ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.8 India 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India ... , registered the fastest GDP growth during the first decade of the 21 ... in Brazil and Russia , along ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... Dr. Elyson and ... tooth removal surgery at their office. Wisdom tooth removal, a common dental procedure, is ... problematic, they often are improperly erupted, resulting in risks of complications. By providing wisdom ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... that supports cellular and metabolic health. This synergistic combination of omega-3 fatty acids ... along with 150 mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). ...
(Date:5/4/2016)... ... 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, ... the same day as her in-office consultation and eye exam. Francesca’s eyesight was restored ...
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy Times ... that it was chosen as the Pharmaceutical News Provider of the Year in ... acknowledge the hard work and dedication of community members who strive to make ...
(Date:5/4/2016)... ... 04, 2016 , ... Bayco Products has announced the introduction ... flashlights in models NSP-9842XL and NSR-9844XL . , First previewed at SHOT ... 2 included CR-123 batteries to produce up to 650 lumens in a variety ...
Breaking Medicine News(10 mins):